2009
Sensitivity of Lipid Metabolism and Insulin Signaling to Genetic Alterations in Hepatic Peroxisome Proliferator–Activated Receptor-γ Coactivator-1α Expression
Estall JL, Kahn M, Cooper MP, Fisher FM, Wu MK, Laznik D, Qu L, Cohen DE, Shulman GI, Spiegelman BM. Sensitivity of Lipid Metabolism and Insulin Signaling to Genetic Alterations in Hepatic Peroxisome Proliferator–Activated Receptor-γ Coactivator-1α Expression. Diabetes 2009, 58: 1499-1508. PMID: 19366863, PMCID: PMC2699879, DOI: 10.2337/db08-1571.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAnimalsBlood GlucoseBody CompositionCell Culture TechniquesCrosses, GeneticFatty LiverFemaleGene Expression RegulationHepatocytesHomeostasisInsulinInsulin ResistanceIntegrasesKetonesLipidsLiverMiceMice, TransgenicPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRNA, Small InterferingTrans-ActivatorsTranscription FactorsTriglyceridesConceptsPGC-1alpha levelsCre/lox systemExpression of genesKey metabolic enzymesKey metabolic pathwaysPGC-1alpha activityPGC-1alpha expressionPeroxisome proliferator-activated receptor gamma coactivatorReceptor γ coactivatorLipid metabolismProliferator-activated receptor gamma coactivatorComplete genetic ablationTranscriptional coactivatorNutrient deprivationReceptor gamma coactivatorPGC-1alphaFatty acid oxidationOxidative phosphorylationMetabolic enzymesLox systemCoactivatorLipid homeostasisMetabolic pathwaysGenetic ablationGenetic alterations
2007
Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-induced Hepatic Steatosis and Insulin Resistance*
Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-induced Hepatic Steatosis and Insulin Resistance*. Journal Of Biological Chemistry 2007, 282: 22678-22688. PMID: 17526931, DOI: 10.1074/jbc.m704213200.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseHepatic insulin resistanceProtein kinase C epsilon activationInsulin resistanceASO treatmentFat-induced hepatic insulin resistanceDiet-induced nonalcoholic fatty liver diseaseDiacylglycerol acyltransferase 2Epsilon activationHigh fat-fed ratsTriglyceride synthesisFatty liver diseaseType 2 diabetesHepatic fatty acid oxidationHepatic insulin sensitivityFat-fed ratsFatty acid oxidationHepatic diacylglycerol contentLiver diseaseHepatic lipidsHepatic steatosisControl ratsInsulin sensitivityPharmacological reductionParadoxical reduction